How to buy China Biologic Products stock - 19 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy China Biologic Products stock

Own China Biologic Products stock in just a few minutes.

China Biologic Products Holdings, Inc is a biotechnology business based in the US. China Biologic Products shares (CBPO) are listed on the NASDAQ and all prices are listed in US Dollars. China Biologic Products employs 2,246 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in China Biologic Products

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for China Biologic Products. Find the stock by name or ticker symbol: CBPO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until China Biologic Products reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of China Biologic Products, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of China Biologic Products. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

China Biologic Products share price

Use our graph to track the performance of CBPO stocks over time.

China Biologic Products shares at a glance

Information last updated 2021-03-18.
52-week rangeUSD$97.91 - USD$120.01
50-day moving average USD$118.36
200-day moving average USD$115.79
Wall St. target priceUSD$102.78
PE ratio 32.7963
Dividend yield N/A (0%)
Earnings per share (TTM) USD$3.57

Buy China Biologic Products shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy China Biologic Products stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is China Biologic Products under- or over-valued?

Valuing China Biologic Products stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of China Biologic Products's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

China Biologic Products's P/E ratio

China Biologic Products's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, China Biologic Products shares trade at around 33x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

China Biologic Products's PEG ratio

China Biologic Products's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.53. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into China Biologic Products's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

China Biologic Products's EBITDA

China Biologic Products's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$208.6 million.

The EBITDA is a measure of a China Biologic Products's overall financial performance and is widely used to measure a its profitability.

China Biologic Products financials

Revenue TTM USD$514.4 million
Operating margin TTM 35.25%
Gross profit TTM USD$329.1 million
Return on assets TTM 5.62%
Return on equity TTM 8.94%
Profit margin 27.42%
Book value $48.63
Market capitalisation USD$4.5 billion

TTM: trailing 12 months

Shorting China Biologic Products shares

There are currently 904,687 China Biologic Products shares held short by investors – that's known as China Biologic Products's "short interest". This figure is 7.6% down from 978,972 last month.

There are a few different ways that this level of interest in shorting China Biologic Products shares can be evaluated.

China Biologic Products's "short interest ratio" (SIR)

China Biologic Products's "short interest ratio" (SIR) is the quantity of China Biologic Products shares currently shorted divided by the average quantity of China Biologic Products shares traded daily (recently around 225046.51741294). China Biologic Products's SIR currently stands at 4.02. In other words for every 100,000 China Biologic Products shares traded daily on the market, roughly 4020 shares are currently held short.

However China Biologic Products's short interest can also be evaluated against the total number of China Biologic Products shares, or, against the total number of tradable China Biologic Products shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case China Biologic Products's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 China Biologic Products shares in existence, roughly 20 shares are currently held short) or 0.04% of the tradable shares (for every 100,000 tradable China Biologic Products shares, roughly 40 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against China Biologic Products.

Find out more about how you can short China Biologic Products stock.

China Biologic Products share dividends

We're not expecting China Biologic Products to pay a dividend over the next 12 months.

China Biologic Products share price volatility

Over the last 12 months, China Biologic Products's shares have ranged in value from as little as $97.91 up to $120.01. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while China Biologic Products's is 0.4209. This would suggest that China Biologic Products's shares are less volatile than average (for this exchange).

China Biologic Products overview

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site